US equities
|
SPCX
$171.09
▲+0.00%
NVDA
$238.90
▲+0.00%
MU
$1,063.96
▲+0.00%
SKHY
$195.02
▲+0.00%
SNDK
$1,704.16
▲+0.00%
SDEV
$3.94
▲+0.00%
TSLA
$378.73
▲+0.00%
INTC
$116.19
▲+0.00%
SPCX
$171.09
▲+0.00%
NVDA
$238.90
▲+0.00%
MU
$1,063.96
▲+0.00%
SKHY
$195.02
▲+0.00%
SNDK
$1,704.16
▲+0.00%
SDEV
$3.94
▲+0.00%
TSLA
$378.73
▲+0.00%
INTC
$116.19
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Biophytis
Biophytis Announces the Drawing of the Second Tranche of Ornane Under the 2021 Atlas Contract for €4 Million
June 30, 2022
From
Biophytis
Via
AccessWire
Topics
Bonds
Tickers
BPTS
Biophytis Presents the Development of Sarconeos (BIO101) in Phase 3 for the Treatment of Sarcopenia at the 15th SCWD International Congress
June 27, 2022
From
Biophytis
Via
AccessWire
Tickers
BPTS
Biophytis: Results of the Combined General Meeting on June 21, 2022
June 22, 2022
From
Biophytis
Via
AccessWire
Tickers
BPTS
Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a Rare Neuromuscular Disease
June 16, 2022
From
Biophytis
Via
AccessWire
Biophytis: Convening of Another Combined General Meeting at a Later Date
June 03, 2022
From
Biophytis
Via
AccessWire
Topics
Regulatory Compliance
Tickers
BPTS
Biophytis: Biophytis Announces its Participation at the BIO International Convention in San Diego from the 13th to the 16th of June
May 12, 2022
From
Biophytis
Via
AccessWire
Tickers
BPTS
Biophytis: Biophytis Presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022
April 19, 2022
From
Biophytis
Via
AccessWire
Tickers
BPTS
Biophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives
April 07, 2022
From
Biophytis
Via
AccessWire
Topics
Initial Public Offering
Tickers
BPTS
Biophytis Provides Updates on Sarconeos (BIO101) Clinical Development
April 07, 2022
From
Biophytis
Via
AccessWire
Tickers
BPTS
Biophytis Appoints Philippe Rousseau as Chief Financial Officer
April 05, 2022
From
Biophytis
Via
AccessWire
Tickers
BPTS
Biophytis will Participate in a Key Workshop on Functional Limitations for the Elderly
March 16, 2022
From
Biophytis
Via
AccessWire
Tickers
BPTS
Biophytis Received Approval from ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients through an Expanded Access Program
February 03, 2022
From
Biophytis
Via
AccessWire
Tickers
BPTS
Biophytis Announces the Drawing of the Last Tranche of ORNANE Under the 2020 Atlas Contract for €3 Million
December 22, 2021
From
Biophytis
Via
AccessWire
Topics
Bonds
Tickers
BPTS
Biophytis to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3
December 16, 2021
From
Biophytis
Via
AccessWire
Tickers
BPTS
Biophytis Obtains a New 10M€ Loan Structure With Kreos Capital
November 22, 2021
From
Biophytis
Via
AccessWire
Topics
Bonds
Regulatory Compliance
Tickers
BPTS
Biophytis Announces US Centers to Restart Recruitment for the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19
November 15, 2021
From
Biophytis
Via
AccessWire
Topics
Regulatory Compliance
Tickers
BPTS
Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021
October 29, 2021
From
Biophytis
Via
AccessWire
Topics
Bonds
Derivatives
Regulatory Compliance
Tickers
BPTS
